Pharmaceuticals

Extended-Release Drugs Market Outlook 2026–2035: Growth Drivers and Industry Forecast

March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the extended-release drugs market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Extended-Release Drugs Market in 2026, and what figure is it projected to hit by 2030?

The market size for extended-release drugs has expanded rapidly in recent years. This segment is projected to grow from $69.63 billion in 2025 to $77.92 billion in 2026, at a compound annual growth rate (CAGR) of 11.9%. Historically, this growth can be attributed to factors such as the increasing prevalence of chronic diseases, a demand for patient-centric drug formulations, the inherent limitations of immediate-release drugs, rising healthcare expenditure, and advancements in pharmaceutical excipients.

The extended-release drugs market size is anticipated to undergo significant growth in the coming years. It is projected to expand to $126.89 billion by 2030, achieving a compound annual growth rate (CAGR) of 13.0%. This growth during the forecast period is primarily attributed to the progression of precision medicine, increased adoption of oral controlled-release formulations, the expansion of hospital and retail pharmacies, a rising geriatric population, and investments in new delivery technologies. Prominent trends for the forecast period include personalized dosage regimens, advanced drug delivery systems, optimization of patient adherence, innovative formulation technologies, and extended-release combination therapies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12675&type=smp

Which Drivers Are Affecting Market Participation In The Extended-Release Drugs Market?

The increasing prevalence of chronic conditions is projected to stimulate the expansion of the extended-release drug market moving forward. Chronic conditions are defined as ailments that persist for a year or longer and require continuous medical care, restrict daily activities, or both. Heart disease, cancer, obesity, and diabetes serve as illustrative examples. Extended-release drug delivery systems are designed to ensure a relatively constant level of medication in the body for an extended period. This helps maintain a consistent therapeutic effect and prevents the fluctuations in drug levels that can occur with immediate-release medications. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, it was predicted that by the year 2050, the number of individuals aged 50 years and older who have at least one chronic illness will surge by 99.5%, escalating to 142.66 million. Therefore, the rising incidence of chronic conditions is a key factor driving the growth of the extended-release drug market.

What Segment Categories Are Covered In The Extended-Release Drugs Market?

The extended-release drugs market covered in this report is segmented –

1) By Type: Sustained Release Drug, Controlled Release Drug

2) By Mode: Over-The-Counter, Prescription

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores

Subsegments:

1) By Sustained Release Drug: Matrix Systems, Coating Systems

2) By Controlled Release Drug: Osmotic Systems, Microencapsulation Systems, Targeted Delivery Systems

Which Trends Are Expected To Influence The Extended-Release Drugs Market In The Upcoming Years?

Leading companies within the extended-release drugs market are actively developing innovative products, including next-generation extended-release tablets, to enhance their offerings and secure a competitive advantage. Extended-release tablets represent a pharmaceutical formulation designed to gradually release their active ingredients over an extended timeframe. For instance, in February 2023, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical firm, received authorization from the U.S. Food and Drug Administration (FDA) for austedo XR (deutetrabenazine). Austedo XR is prescribed for adults experiencing chorea and tardive dyskinesia associated with Huntington disease. It is supplied in dosages of 6, 12, and 24 mg. With the approval of austedo XR, patients diagnosed with tardive dyskinesia and Huntington disease chorea now have an additional effective treatment option. This enables individuals to manage these disorders with medication administered once daily. The development of austedo XR, which offers a practical and efficient therapeutic alternative for those with specific movement disorders, signifies a considerable advancement in the management of these conditions.

Which Key Market Players Are Investing In Expansion And Innovation Within The Extended-Release Drugs Market?

Major companies operating in the extended-release drugs market are Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi SA, GlaxoSmithKline PLC, AstraZeneca Plc, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Purdue Pharma LP, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Mallinckrodt LLC, Allergan plc, Janssen Pharmaceuticals Inc., Noven Pharmaceuticals Inc., Mayne Pharma Group Ltd., Neos Therapeutics Inc., Oakwood Laboratories LLC, Roxane Laboratories Inc., Watson Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/extended-release-drugs-global-market-report

Which Regions Are Poised For Strategic Growth In The Extended-Release Drugs Market?

North America was the largest region in the extended-release drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the extended-release drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Extended-Release Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12675&type=smp

Browse Through More Reports Similar to the Global Extended-Release Drugs Market 2026, By The Business Research Company

Extended Release Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/extended-release-drugs-global-market-report

Controlled Release Drug Delivery Market Report 2026

https://www.thebusinessresearchcompany.com/report/controlled-release-drug-delivery-global-market-report

Pharmaceutical Drug Delivery Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795